

Supplemental Table for:  
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2-Positive Breast Cancer: A Real-World Study from China  
Jianbin Li et al.

**Table S1.** Courses of trastuzumab use in EBC and MBC

Status of drug use	Reasons	EBC (n, %)		MBC (n, %)	
		≤6m	>6m	≤6m	>6m
End in use	Disease progression	20 (10.3)	28 (12.9)	28 (13.0)	70 (22.7)
	Financial problem	11 (5.6)	1 (0.5)	16 (7.4)	71 (23.0)
	Drug tolerance	2 (1.0)	2 (0.9)	11 (5.1)	12 (3.9)
	Course completion	0 (0)	139 (64.1)	9 (4.2)	0 (0)
	Others	7 (3.6)	16 (7.4)	6 (2.8)	3 (0.9)
Median time of drug use (m)		12m		10m	
Still in use		155 (79.5)	31 (14.3)	146 (67.4)	153 (49.5)
Overall		195	217	216	309

Others: clinical trials, loss of follow-up ect.